Immunocore Holdings plc Net Fee Amt
Immunocore Holdings plc (IMCR) had Net Fee Amt of $9.77 thousand as of 2026-05-08, per its S-8 filed 2026-05-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-08
- 2026-05-08: Net Fee Amt $9.77K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-08 | $9.77K S-8 · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |